Destiny Pharma plc: Expansion of clinical pipeline

Brighton, United Kingdom – 27 September 2021 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, is pleased to announce that the Company’s China regional partner and investor, China Medical System Holdings Limited (CMS), is establishing a new programme with XF-73 targeting the prevention and treatment of superficial skin infections caused by bacteria.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...